Dimethyl sulfoxide (DMSO) serves three distinct roles in oncology API production: a reaction solvent for reductions and heterocycle assembly, a recrystallization medium for purification, and — in one marketed drug — a structural component of the active substance itself.
Where DMSO Is Used in Oncology APIs
Capecitabine uses DMSO in a sodium borohydride reduction on its nucleoside sugar moiety, where a DMSO–petroleum ether biphasic system dissolves both the polar substrate and the borohydride while controlling over-reduction. 5-Fluorouracil is purified by hot-DMSO recrystallization, exploiting selective solubility that rejects impurities on cooling.
Imatinib and gefitinib both use DMSO as the polar aprotic solvent for pyrimidine and quinazoline ring construction, attaching side chains through nucleophilic aromatic substitution. Trametinib (Mektovi®, CAS 1187431-43-1) is the exceptional case: the marketed API is a 1:1 DMSO solvate, with DMSO locked into the crystal lattice rather than removed as a residual solvent.
| Drug | DMSO Role |
|---|---|
| Capecitabine | NaBH₄ reduction solvent (biphasic) |
| 5-Fluorouracil | Hot recrystallization / purification |
| Imatinib | Pyrimidine condensation & N-alkylation |
| Gefitinib | Quinazoline synthesis & morpholine SNAr |
| Trametinib | DMSO solvate is the API itself |
Table 1: DMSO roles across five anti-tumor APIs
Process Conditions and Quality Control
For the borohydride reduction in capecitabine, DMSO is dried to below 0.1% water because residual moisture quenches NaBH₄ and generates hydrogen gas, while the biphasic DMSO–petroleum ether system keeps the reduction selective by limiting contact between the borohydride and the more reducible functional groups on the nucleoside. Reaction temperatures are held at 0–25 °C, with HPLC monitoring to stop at full conversion before over-reduction of the lactol.
In the SNAr steps for imatinib and gefitinib, anhydrous DMSO at 80–120 °C dissolves both the heteroaryl chloride and the amine nucleophile, giving homogeneous substitution without a phase-transfer catalyst. Residual DMSO is removed by vacuum distillation or aqueous extraction, and its Class 3 status under ICH Q3C means the 50 mg/day permitted daily exposure is rarely limiting for oral oncology APIs.
Why DMSO Rather Than DMF or NMP
DMSO dissolves both polar nucleoside intermediates and inorganic borohydrides in a single phase, whereas DMF struggles with substrate solubility and NMP is classified as a reproductive toxin under REACH. For the SNAr steps in imatinib and gefitinib, DMSO leaves anions more reactive than DMF, giving cleaner coupling at manufacturing scale. Its 189 °C boiling point permits high-temperature operation without pressure equipment, and its Class 3 status under ICH Q3C (50 mg/day PDE) makes residual removal straightforward for the four non-solvate drugs.
Pharmaceutical-grade DMSO meeting USP monograph requirements is used throughout, with the tight water specification mattering most for the borohydride reduction and anhydrous SNAr couplings. For trametinib, DMSO is not a residual to be minimized but a defined structural component of the API specification, required for the physical stability and bioavailability of the solvate form.
References
- ICH Harmonised Tripartite Guideline Q3C(R6): Impurities — Guideline for Residual Solvents, 2019.
- United States Pharmacopeia, USP Monograph <679> Dimethyl Sulfoxide.
- Trametinib DMSO solvate (Mektovi®, CAS 1187431-43-1), Novartis.